Alpha-1 Antitrypsin Deficiency (A1AD) Pipeline Review, H2 2020: Therapeutic Analysis of 27 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alpha-1 Antitrypsin Deficiency (A1AD) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Alpha-1 Antitrypsin Deficiency (A1AD) – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide also reviews the key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 16, 3 and 2 respectively.

Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
• The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

(Read more…)

• The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

• Alpha-1 Antitrypsin Deficiency (A1AD) – Overview
• Alpha-1 Antitrypsin Deficiency (A1AD) – Therapeutics Development

Alpha-1 Antitrypsin Deficiency (A1AD) – Therapeutics Assessment

Alpha-1 Antitrypsin Deficiency (A1AD) – Companies Involved in Therapeutics Development

Alpha-1 Antitrypsin Deficiency (A1AD) – Drug Profiles

Alpha-1 Antitrypsin Deficiency (A1AD) – Dormant Projects

• Alpha-1 Antitrypsin Deficiency (A1AD) – Discontinued Products
• Alpha-1 Antitrypsin Deficiency (A1AD) – Product Development Milestones

Appendix

Companies Mentioned

• Alnylam Pharmaceuticals Inc
• Apic Bio Inc
• Applied Genetic Technologies Corp
• Arrowhead Pharmaceuticals Inc
• Beam Therapeutics Inc
• Dicerna Pharmaceuticals Inc
• Editas Medicine Inc
• Evolve Biologics Inc
• Grifols SA
• Inhibrx Inc
• Intellia Therapeutics Inc
• International Stem Cell Corp
• Kamada Ltd
• LEXEO Therapeutics LLC
• Liminal BioSciences Inc
• Logicbio Therapeutics Inc
• Mereo Biopharma Group Plc
• Moderna Inc
• pH Pharma Co Ltd
• PlantForm Corp
• Promethera Biosciences SA
• Renovion Inc
• Santhera Pharmaceuticals Holding AG
• Takeda Pharmaceutical Co Ltd
• Vera Therapeutics Inc
• Vertex Pharmaceuticals Inc
• Z Factor Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h80nro

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900